PATENT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant

Pastor et al.

Serial. No

10/647,739

Examiner: Not Yet Assigned

Filed

August 25, 2003

Group Art Unit: 1632

For

THERAPY WITH CANNABINOID COMPOUNDS FOR THE

TREATMENT OF BRAIN TUMORS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

January 6, 2004

Date of Deposit

Bradlevin

Maragan

ignature

27,551

PTO Registration No.

January 7, 2004

Date of Signature

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicant brings to the attention of the Examiner the documents listed on the attached PTO 1449 and respectfully requests that the listed documents be considered by the Examiner and made of record in the above-captioned application. Unless otherwise indicated, a full text copy of each document is attached. The referenced citations are listed in the accompanying International Search Report and PTO Form 1449.

A34700 PCT USA-I - 069277.0113

PATENT

Identification of the listed references in the PTO 1449 is not to be construed as an admission of the Applicant(s) or the attorneys of the Applicant(s) that such references are available as "prior art" against the subject application.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicant determines that the cited document(s) do not constitute "prior art" under United States law, applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

This statement is submitted more than 3 months from the application filing date but before the mailing date of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.98, submission of this Information Disclosure Statement requires no fee. However, the Commissioner is hereby authorized to charge the payment of any fees required in association with this communication to Deposit Account No. 02-4377.

Respectfully submitted,

Bradley B. Geist

Patent Office Reg. No. 27,551

30 Rockefeller Plaza 44th Floor

New York, NY 10112

(212) 408-2500

Attorneys for Applicant

JAN 1 2 2004		
Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT	Atty. Docket No. A34700 PCT USA-I (069277.0113) Applicant Pastor et al.	
BY APPLICANT (Use several sheets if necessary)	Filing Date April 25, 2003	Group 1632

Exam. Init.	_		D	ocument	No.		S. PATENT DO Date	Name	Class	Subclass	Filing Date if Appro.	
							·					
					I	ORE	IGN PATEN	T DOCUMENTS	S	-		
		Document No.					Date	Country	Class	Subclass	Trans Yes	slation No
	•		ОТН	ER D	OCUN	MENT	'S (including A	uthor, Title, Date, Po	ertinent Page	s Etc.)	·	·
			RRIS,	L.S.,	et al.,	"Ret		umor growth by			binol"	, The
		szara Drug	a(ed) l g Abus	Pharm se. Pr	acolog oceedi	y of r	narihuana", v the Meeting	erties of cannabing ol. 1 γ2-A monog Savanah, GA, US 4-067-2, 1976, pp.:	graph of the A. Dic. 3-6	National	Instit	ute o
		BAE	EK SE	UNG-	HWA,	et al.	"Synthesis a	and antitumor active, pp.228-230.		abigerol",	Archi	ves o
		reag	ent (V	II). A	Antitur	nor ac	tivity of can	fluoride etherate nabigerol against , June 1998, vol. 2	human oral	epitheloid		
			Z et a	l., "∆-	9 tetra	hydro	cannabinol in	duces apoptois in	human pro	state PC-3	cells	via

NY02:361207.1 Examiner	Date Considered	

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.